Mechanistic support is added for the effects of Lut on redox balance and inflammation in these AD models by inhibited intracellular ROS generation and decreased the production of cytokines that promote inflammation in activated HaCaT cells.
Abstract
Atopic dermatitis (AD) features persistent or recurrent skin inflammation, with oxidative stress also implicated in its development. Luteolin (Lut), a flavonoid sourced from plants, has been reported to attenuate inflammatory and oxidative responses; its effects in experimental AD require further characterization. To assess Lut in vivo and in vitro, we used 2,4-dinitrochlorobenzene (DNCB) to induce AD-like skin lesions in mice and exposed HaCaT keratinocytes to tumor necrosis factor-α (TNF-α) plus interferon-γ (IFN-γ). Luteolin treatment improved AD-like skin manifestations, reduced serum IgE levels, and alleviated histopathological alterations in DNCB-treated mice. Furthermore, elevated doses of Lut markedly diminished malondialdehyde (MDA) levels, whereas Lut lowered reactive oxygen species (ROS) concentrations, reinstated superoxide dismutase (SOD) activity, and mitigated inflammatory reactions in dermal tissues. In vitro, Lut inhibited intracellular ROS generation and decreased the production of cytokines that promote inflammation in activated HaCaT cells. Further experiments involving Nrf2 immunofluorescence and siRNA-induced knockdown of Nrf2 showed greater nuclear accumulation of Nrf2 after Lut treatment and supported a functional role for Nrf2 in Lut-induced changes in HO-1 and NQO1 expression and NF-κB phosphorylation. Together, these results add mechanistic support for the effects of Lut on redox balance and inflammation in these AD models.
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by immune dysregulation and epidermal barrier dysfunction. The essential oil of Helichrysum (HEO) possesses known anti-inflammatory properties, yet its therapeutic efficacy and underlying mechanisms in AD remain to be fully elucidated. This stu...
Yong-Qi Chen, Zhong-Ying Xu, Li-Ming Mao et al.· Current Issues in Molecular...· 0 citations
It is demonstrated that ROF exerts favorable inhibitory effects against AD-like inflammation both in vivo and in vitro, underscoring its potential as a viable therapeutic option for managing AD and other inflammatory cutaneous disorders.
Background Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by skin barrier dysfunction and immune activation. Antioxidants such as sulforaphane (SFN) have shown benefit in mouse models of AD and are being explored as topical therapies. Objectives We investigated the immune mechanisms through...
A. Tukanowicz-Hassett, S. Bapat, Yuichi Yokoyama et al.· bioRxiv· 0 citations
AL significantly improves AD, potentially by inhibiting miR-31-5p expression to reduce inflammatory responses and improve keratinocyte function, and provides a novel therapeutic target for AD.
Chronic exposure to ultraviolet (UV) radiation is the dominant environmental driver of premature skin ageing. UVB is absorbed mainly in the epidermis, whereas the more abundant UVA reaches the dermis; together they generate reactive oxygen species, activate MAPK, AP-1 and NF-κB signalling, depress Nrf2-dependent defenc...
Sushil Kumar, Vishal Kumar, S. Kushwaha et al.· Iconic research and engineer...· 0 citations
Resveratrol was associated with improved keratinocyte migration under LPS-induced inflammatory conditions, and may be a promising modulator of inflammatory wound microenvironments, which are characterized by impaired re-epithelialization, oxidative stress, and persistent inflammatory signaling.
S. Dumur, Burcu Biltekin, Hafize Uzun· Turkish Journal of Biology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.